Want to see AU:S66 full AI Analyst Report?
S66 Stock Chart & Stats
AU$0.25
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.25
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.11 - AU$0.28
Previous CloseN/A
Volume100.00K
Average Volume (3M)6.77K
Market Cap
AU$18.23M
Enterprise ValueAU$20.41M
Total Cash (Recent Filing)AU$18.18M
Total Debt (Recent Filing)AU$8.29M
Price to Earnings (P/E)4.3
Beta-0.79
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.54%
Share Statistics
EPS (TTM)0.03
Shares Outstanding135,002,980
10 Day Avg. Volume4,300
30 Day Avg. Volume6,768
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.63
Price to Sales (P/S)0.86
P/FCF Ratio2.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Free Cash Flow StrengthReported 2025 free cash flow of roughly $11.5M and near 1:1 conversion with net income demonstrates strong internal cash generation capacity. Durable FCF supports operations, dividends or debt reduction and provides management optionality for capital allocation over the next 2–6 months.
Conservative LeverageA debt-to-equity ratio near 0.10 indicates a conservative balance sheet and low financial risk. This structural strength gives the company flexibility to absorb revenue volatility, fund strategic investments or maintain distributions without relying on expensive external financing in the medium term.
Margin ReboundA significant jump in net margin to ~18.9% and higher gross margin suggest improved pricing, mix or cost control. If these are structural improvements, they raise sustainable earnings power and cash conversion, helping the business remain profitable even if volumes soften over the coming months.
Bears Say
Revenue DeclineTop-line fell about 6.3% in 2025 and recent multi-year revenue growth metrics are negative, indicating demand or share pressures. Reliance on margin gains rather than consistent volume growth makes earnings recovery vulnerable if revenue weakness persists across the next several quarters.
Earnings & Cash VolatilityThe company has a history of swings—losses in 2021–2023 and negative cash flow in 2024—so 2025's positive results may be episodic. This inconsistent track record increases execution risk and reduces confidence that the 2025 turnaround will be sustained into subsequent reporting periods.
Small ScaleA headcount of ~30 signals a small operating footprint in the Household & Personal Products industry. Limited scale can constrain R&D, distribution reach, purchasing power and the ability to absorb shocks, making it harder to sustain growth and competitive positioning over the medium term.
Star Combo Pharma Ltd. News
S66 FAQ
What was Star Combo Pharma Ltd.’s price range in the past 12 months?
Star Combo Pharma Ltd. lowest share price was AU$0.11 and its highest was AU$0.28 in the past 12 months.
What is Star Combo Pharma Ltd.’s market cap?
Star Combo Pharma Ltd.’s market cap is AU$18.23M.
When is Star Combo Pharma Ltd.’s upcoming earnings report date?
Star Combo Pharma Ltd.’s upcoming earnings report date is Aug 25, 2026 which is in 55 days.
How were Star Combo Pharma Ltd.’s earnings last quarter?
Star Combo Pharma Ltd. released its earnings results on Feb 25, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.
Is Star Combo Pharma Ltd. overvalued?
According to Wall Street analysts Star Combo Pharma Ltd.’s price is currently Overvalued.
Does Star Combo Pharma Ltd. pay dividends?
Star Combo Pharma Ltd. pays a Notavailable dividend of AU$0.004 which represents an annual dividend yield of 1.54%. See more information on Star Combo Pharma Ltd. dividends here
What is Star Combo Pharma Ltd.’s EPS estimate?
Star Combo Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Star Combo Pharma Ltd. have?
Star Combo Pharma Ltd. has 135,002,980 shares outstanding.
What happened to Star Combo Pharma Ltd.’s price movement after its last earnings report?
Star Combo Pharma Ltd. reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.878%.
Which hedge fund is a major shareholder of Star Combo Pharma Ltd.?
Currently, no hedge funds are holding shares in AU:S66
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Star Combo Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.20%
12-Months-Change
Fundamentals
Return on Equity
14.06%
Trailing 12-Months
Asset Growth
8.47%
Trailing 12-Months
Company Description
Star Combo Pharma Ltd.
Star Combo Pharma Limited is involved in the production and supply of health foods and dietary supplements across Australia and China. The company's activities are organized into two primary divisions: Star Combo and Austoyou Retail. It manages the full spectrum of natural health supplements and skincare products, encompassing their development, manufacturing, promotion, and sale. Distribution channels include a dedicated e-commerce platform for health-conscious consumers in China, alongside two brick-and-mortar retail stores situated in Sydney. Founded in 2004, Star Combo Pharma Limited's main office is located in Smithfield, Australia.
Technical Analysis
Zoono Group Limited
―
Nanollose Ltd.
―
Skin Elements Limited
―
Lumos Diagnostics Holdings Ltd.
―
―